Navigation Links
JCI early table of contents for July 9, 2012
Date:7/9/2012

Breathing easy: keeping airways open

Asthma is an increasingly common chronic disorder characterized by wheezing and shortness of breath. Symptoms are caused by excessive airway smooth muscle contraction; however mechanisms serving to keep airways open are not fully understood. Dean Sheppard and colleagues at the University of California at San Francisco have revealed a pathway required for preventing exaggerated airway smooth muscle contraction. Their work investigates a protein called α9β1, which is highly expressed in airway smooth muscle, and makes use of a mouse model that lacks α9β1 in smooth muscle. These mice exhibited increased airway narrowing, suggesting that α9β1 inhibits smooth muscle contraction. The enzyme SSAT, which breaks down polyamines such as spermine and spermidine, is known to bind α9β1 and is required for α9β1-mediated cell movement. Their results show that SSAT is also involved in restraining airway smooth muscle contraction, likely downstream of α9β1. Their work provides insight into a pathway counteracting airway contraction, which could be used to develop treatment options that prevent asthma symptoms.

TITLE:
Integrin α9β1 in airway smooth muscle suppresses exaggerated airway narrowing

AUTHOR CONTACT:
Dean Sheppard
UCSF, San Francisco, CA, USA
Phone: 415-514-4269; Fax: 415-514-4278; E-mail: dean.sheppard@ucsf.edu

View this article at: http://www.jci.org/articles/view/60387?key=85724bb916ec4ac0fed8


METABOLISM

Crosstalk between glucose and lipid metabolism

Regulating metabolism requires coordination of the production, storage, and breakdown of nutrients in response to both availability and demand. Such regulation requires complex pathways to control the activity of metabolic enzymes and the rate at which metabolic genes are transcribed. Dr. Kristina Schoonjans and co-workers at the Ecole Polytechnique Fdrale in Lausanne, Switzerland report on the role of liver receptor homolog 1 (LRH-1), a transcription factor with important functions in lipid metabolism and reverse cholesterol transport. Their work uncovers new functions for LRH-1 in sensing and responding to glucose. In mice with conditional deletion of Lrh1 in liver, they observed impaired glucose production, reductions in the storage of glucose as liver glycogen, and less lipid generation in response to glucose exposure. Their work demonstrates that LRH-1 is important for glucose-sensing and for coordinating glucose and lipid metabolism after feeding.

TITLE:
LRH-1dependent glucose sensing determines intermediary metabolism in liver

AUTHOR CONTACT:
Kristina Schoonjans
Ecole Polytechnique Fdrale de Lausanne, Lausanne, CHE
Phone: +41216931891; E-mail: kristina.schoonjans@epfl.ch

View this article at: http://www.jci.org/articles/view/62368?key=c1bf94afdd9381c598fc


ONCOLOGY

Decreasing cancer risk associated with inflammatory bowel disease

Inflammatory bowel disease is caused by chronic inflammation , which leads to damage of the intestinal epithelium. Patients with inflammatory bowel disease have an elevated risk for developing colorectal cancer because of this chronic inflammation. In an effort to develop strategies to break the cycle of inflammation, Dr. Brent Polk and colleagues at the University of Southern California in Los Angeles examined two mouse models of colorectal cancer. Their work shows that inactivating a key receptor, known as epidermal growth factor receptor, increases the frequency and severity of colorectal tumors. Though epidermal growth factor has well-defined roles in promoting tumor growth, the Polk team now finds that epidermal growth factor receptor can ameliorate the response to chronic inflammation and reduces tumor development by fine-tuning inflammation and the generation of intestinal epithelium. Their results suggest that promoting epidermal growth factor activity in patients with inflammatory bowel disease could decrease long-term cancer risk by reducing inflammation.

TITLE:
Epidermal growth factor receptor inhibits colitis-associated cancer in mice

AUTHOR CONTACT:
D. Brent Polk
University of Southern California and Childrens Hospital Los Angeles, Los Angeles, CA, USA
Phone: 323-361-2278; E-mail: dbpolk@chla.usc.edu

View this article at: http://www.jci.org/articles/view/62888?key=ab673ae8215aaf449677


ONCOLOGY

Differentiating effects on skin cancer

Squamous cell carcinomas (SCCs), which are the most aggressive form of non-melanoma skin cancer, typically have functional impairment in the tumor suppressor protein p53. Dr. Erwin F. Wagner and colleagues from the Centro Nacional de Investigaciones Oncologicas in Madrid, Spain recently uncovered new mechanisms mediating p53 impairment and its role in SCC tumor suppression. They found that deletion of the Fos gene reduced tumor development in a mouse model of skin carcinogenesis. The FOS protein was found to directly repress p53, preventing its tumor suppression function. Deleting Fos and the gene encoding p53 together resulted in tumors with impaired differentiation. The Wagner team went onto show that p53 directly upregulates TACE, a metalloprotease, involved in cell differentiation. Levels of FOS in human tumor tissue correlated with inactive TACE expression and poorly differentiated tumors. Lastly, the combination of FOS inhibition and the presence of a normal gene encoding p53 caused differentiation and inhibited proliferation in cells derived from human SCCs. These results suggest inhibition of FOS and activation of the p53-TACE axis could be considered as future treatments for SCC.

TITLE:
Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17

AUTHOR CONTACT:
Erwin F. Wagner
CNIO, Madrid, UNK, ESP
E-mail: ewagner@cnio.es

View this article at: http://www.jci.org/articles/view/63103?key=4ba08a4ecb33e87c7648


'/>"/>

Contact: Sarah Jackson
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Discovery improves understanding of early onset inflammatory disease
2. Kids Born Even a Little Early Have Lower School Scores: Study
3. Rheumatoid arthritis takes high toll in unemployment, early death, Mayo Clinic finds
4. UT Southwestern study shows treating diabetes early, intensively is best strategy
5. Early Surgery May Benefit Some With Heart Infection
6. After child dies, moms risk of early death skyrockets: study
7. Fossilized Teeth Hold Clues to Early Human Species Diet
8. JCI early table of contents for June 18, 2012
9. Early Menopause May Raise Risk for Brain Aneurysm
10. Lung changes are present in nearly half of ACPA positive RA patients at disease onset
11. Early menopause predicts a milder form of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: